$ACTC Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Ocata Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Ocata Therapeutics, Inc.. Get notifications about new insider transactions in Ocata Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 18 2013 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 0.06 | 125,000 | 7,500 | 125,000 | |
Nov 18 2013 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 0.06 | 125,000 | 7,500 | 125,000 | |
Nov 12 2013 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | A | 0.06 | 1,285,714 | 79,714 | 1,285,714 | |
Nov 12 2013 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 1,285,714 | 0 | 23,943,822 | 25.2 M to 23.9 M (-5.10 %) |
Oct 02 2013 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 555,177 | 0 | 18,833,542 | 18.3 M to 18.8 M (+3.04 %) |
Oct 02 2013 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 1,016,667 | 891.7 K to 1 M (+14.02 %) |
Oct 02 2013 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 1,058,333 | 933.3 K to 1.1 M (+13.39 %) |
Oct 02 2013 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 4,100,000 | 4 M to 4.1 M (+3.14 %) |
Oct 02 2013 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 125,000 | 0 | 850,000 | 725 K to 850 K (+17.24 %) |
Jul 01 2013 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 543,831 | 0 | 15,594,167 | 15.1 M to 15.6 M (+3.61 %) |
Jul 01 2013 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 891,667 | 766.7 K to 891.7 K (+16.30 %) |
Jul 01 2013 | ACTC | Ocata Therapeutics ... | Myles Edward H | CFO and EVP of Corp ... | Option Exercise | A | 0.08 | 14,000,000 | 1,089,200 | 14,000,000 | |
Jul 01 2013 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 933,333 | 808.3 K to 933.3 K (+15.46 %) |
Jul 01 2013 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 3,975,000 | 3.9 M to 4 M (+3.25 %) |
Jul 01 2013 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 125,000 | 0 | 725,000 | 600 K to 725 K (+20.83 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 1,000,000 | 79,200 | 6,000,001 | 7 M to 6 M (-14.29 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.07 | 650,000 | 45,565 | 7,000,001 | 7.7 M to 7 M (-8.50 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.07 | 350,000 | 25,025 | 7,650,001 | 8 M to 7.7 M (-4.37 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 391,444 | 32,098 | 8,000,001 | 8.4 M to 8 M (-4.66 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 608,556 | 50,023 | 8,391,445 | 9 M to 8.4 M (-6.76 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 1,000,000 | 78,400 | 9,000,001 | 10 M to 9 M (-10.00 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.07 | 350,000 | 25,375 | 10,000,001 | 10.4 M to 10 M (-3.38 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 24,500 | 1,960 | 10,350,001 | 10.4 M to 10.4 M (-0.24 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 80,000 | 6,440 | 10,374,501 | 10.5 M to 10.4 M (-0.77 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 95,471 | 7,666 | 10,454,501 | 10.5 M to 10.5 M (-0.90 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.07 | 388,090 | 26,584 | 10,549,972 | 10.9 M to 10.5 M (-3.55 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.07 | 290,000 | 20,793 | 10,938,062 | 11.2 M to 10.9 M (-2.58 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 122,000 | 9,821 | 11,228,062 | 11.4 M to 11.2 M (-1.07 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 199,910 | 16,653 | 11,350,062 | 11.5 M to 11.4 M (-1.73 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.18 | 625,000 | 109,500 | 11,549,972 | 12.2 M to 11.5 M (-5.13 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.14 | 720,920 | 104,389 | 12,174,972 | 12.9 M to 12.2 M (-5.59 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.14 | 787,429 | 111,657 | 12,895,892 | 13.7 M to 12.9 M (-5.75 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.15 | 491,650 | 71,388 | 13,683,321 | 14.2 M to 13.7 M (-3.47 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.17 | 539,987 | 91,690 | 14,174,971 | 14.7 M to 14.2 M (-3.67 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.16 | 707,913 | 115,956 | 14,714,958 | 15.4 M to 14.7 M (-4.59 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.16 | 135,100 | 21,940 | 15,422,871 | 15.6 M to 15.4 M (-0.87 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.17 | 667,000 | 110,322 | 15,557,971 | 16.2 M to 15.6 M (-4.11 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.19 | 266,898 | 51,938 | 16,224,971 | 16.5 M to 16.2 M (-1.62 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.18 | 733,102 | 130,126 | 16,491,869 | 17.2 M to 16.5 M (-4.26 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.17 | 390,993 | 68,072 | 17,224,971 | 17.6 M to 17.2 M (-2.22 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.19 | 250,000 | 47,225 | 17,615,964 | 17.9 M to 17.6 M (-1.40 %) |
Apr 15 2013 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.19 | 250,000 | 48,700 | 17,865,964 | 18.1 M to 17.9 M (-1.38 %) |
Apr 01 2013 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 525,534 | 0 | 15,050,336 | 14.5 M to 15.1 M (+3.62 %) |
Apr 01 2013 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 766,667 | 641.7 K to 766.7 K (+19.48 %) |
Apr 01 2013 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 808,333 | 683.3 K to 808.3 K (+18.29 %) |
Apr 01 2013 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 3,850,000 | 3.7 M to 3.9 M (+3.36 %) |
Apr 01 2013 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 125,000 | 0 | 600,000 | 475 K to 600 K (+26.32 %) |
Feb 26 2013 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 0.06 | 500,000 | 28,950 | 500,000 | |
Feb 26 2013 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | A | 0.06 | 500,000 | 28,950 | 500,000 | |
Feb 26 2013 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | A | 0.06 | 500,000 | 28,950 | 500,000 | |
Feb 26 2013 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | A | 0.06 | 500,000 | 28,950 | 500,000 | |
Feb 26 2013 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | A | 0.06 | 500,000 | 28,950 | 500,000 | |
Jan 04 2013 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 580,348 | 0 | 14,524,802 | 13.9 M to 14.5 M (+4.16 %) |
Jan 04 2013 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 641,667 | 516.7 K to 641.7 K (+24.19 %) |
Jan 04 2013 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 683,333 | 558.3 K to 683.3 K (+22.39 %) |
Jan 04 2013 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 3,725,000 | 3.6 M to 3.7 M (+3.47 %) |
Jan 04 2013 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 125,000 | 0 | 475,000 | 350 K to 475 K (+35.71 %) |
Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 43,000 | 2,580 | 26,476,227 | 26.5 M to 26.5 M (-0.16 %) |
Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 100,000 | 5,940 | 26,519,227 | 26.6 M to 26.5 M (-0.38 %) |
Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 150,000 | 8,895 | 26,619,227 | 26.8 M to 26.6 M (-0.56 %) |
Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 545,490 | 32,184 | 26,769,227 | 27.3 M to 26.8 M (-2.00 %) |
Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 40,000 | 2,340 | 27,314,717 | 27.4 M to 27.3 M (-0.15 %) |
Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 440,000 | 25,520 | 27,354,717 | 27.8 M to 27.4 M (-1.58 %) |
Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.06 | 20,000 | 1,158 | 27,794,717 | 27.8 M to 27.8 M (-0.07 %) |
Dec 18 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 1,285,714 | 0 | 27,814,717 | 26.5 M to 27.8 M (+4.85 %) |
Oct 24 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 452,117 | 0 | 13,944,454 | 13.5 M to 13.9 M (+3.35 %) |
Oct 03 2012 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 3,600,000 | 3.5 M to 3.6 M (+3.60 %) |
Oct 03 2012 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 516,667 | 391.7 K to 516.7 K (+31.91 %) |
Oct 03 2012 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 558,333 | 433.3 K to 558.3 K (+28.85 %) |
Oct 03 2012 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 125,000 | 0 | 350,000 | 225 K to 350 K (+55.56 %) |
Aug 09 2012 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | A | 0.09 | 500,000 | 42,500 | 500,000 | |
Aug 09 2012 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | A | 0.09 | 500,000 | 42,500 | 500,000 | |
Aug 09 2012 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | A | 0.09 | 500,000 | 42,500 | 500,000 | |
Aug 02 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | A | 0.09 | 500,000 | 42,500 | 500,000 | |
Aug 02 2012 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 0.08 | 362,022 | 30,410 | 362,022 | |
Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 500,000 | 40,000 | 26,529,003 | 27 M to 26.5 M (-1.85 %) |
Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 190,000 | 15,580 | 27,029,003 | 27.2 M to 27 M (-0.70 %) |
Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 546,793 | 44,290 | 27,219,003 | 27.8 M to 27.2 M (-1.97 %) |
Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 151,500 | 12,135 | 27,765,796 | 27.9 M to 27.8 M (-0.54 %) |
Aug 01 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 611,707 | 48,937 | 27,917,296 | 28.5 M to 27.9 M (-2.14 %) |
Jul 26 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 1,285,714 | 0 | 28,529,003 | 27.2 M to 28.5 M (+4.72 %) |
Jul 26 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 1,285,714 | 0 | 27,243,289 | 26 M to 27.2 M (+4.95 %) |
Jul 16 2012 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 433,333 | 308.3 K to 433.3 K (+40.54 %) |
Jul 10 2012 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 3,475,000 | 3.4 M to 3.5 M (+3.73 %) |
Jul 10 2012 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 125,000 | 0 | 225,000 | 100 K to 225 K (+125.00 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | A | 0.19 | 500,000 | 95,000 | 500,000 | |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | A | 1.35 | 50,000 | 67,500 | 50,000 | |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | A | 2.48 | 50,000 | 124,000 | 50,000 | |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 509,720 | 0 | 23,488,061 | 23 M to 23.5 M (+2.22 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 292,832 | 0 | 22,978,341 | 22.7 M to 23 M (+1.29 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 125,000 | 0 | 22,685,529 | 22.6 M to 22.7 M (+0.55 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 5,532,198 | 0 | 22,560,509 | 17 M to 22.6 M (+32.49 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 13,846 | 0 | 17,028,311 | 17 M to 17 M (+0.08 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 500,000 | 0 | 17,014,465 | 16.5 M to 17 M (+3.03 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 100,982 | 0 | 16,514,465 | 16.4 M to 16.5 M (+0.62 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 406,324 | 0 | 16,413,483 | 16 M to 16.4 M (+2.54 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 554,845 | 0 | 16,007,159 | 15.5 M to 16 M (+3.59 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 798,184 | 0 | 15,452,314 | 14.7 M to 15.5 M (+5.45 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 683,273 | 0 | 14,654,130 | 14 M to 14.7 M (+4.89 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 559,979 | 0 | 13,970,857 | 13.4 M to 14 M (+4.18 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 593,662 | 0 | 13,410,878 | 12.8 M to 13.4 M (+4.63 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 473,649 | 0 | 12,817,216 | 12.3 M to 12.8 M (+3.84 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 584,310 | 0 | 12,343,567 | 11.8 M to 12.3 M (+4.97 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 447,376 | 0 | 11,759,257 | 11.3 M to 11.8 M (+3.95 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 416,229 | 0 | 11,311,881 | 10.9 M to 11.3 M (+3.82 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 882,604 | 0 | 10,895,652 | 10 M to 10.9 M (+8.81 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 5,000,000 | 0 | 10,013,048 | 5 M to 10 M (+99.74 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 424,736 | 0 | 5,013,048 | 4.6 M to 5 M (+9.26 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 437,494 | 0 | 4,588,312 | 4.2 M to 4.6 M (+10.54 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 391,667 | 266.7 K to 391.7 K (+46.87 %) |
Jul 09 2012 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Grant | A | 0.00 | 1,000,000 | 0 | 15,262,401 | 14.3 M to 15.3 M (+7.01 %) |
Jun 19 2012 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.07 | 350,000 | 25,095 | 14,262,401 | 14.6 M to 14.3 M (-2.40 %) |
Jun 19 2012 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.07 | 300,000 | 21,240 | 14,612,401 | 14.9 M to 14.6 M (-2.01 %) |
Jun 19 2012 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.08 | 175,029 | 13,127 | 14,912,401 | 15.1 M to 14.9 M (-1.16 %) |
Apr 18 2012 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 100,000 | 0 | 100,000 | 0 to 100 K |
Apr 04 2012 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 308,333 | 183.3 K to 308.3 K (+68.18 %) |
Apr 04 2012 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 266,667 | 141.7 K to 266.7 K (+88.24 %) |
Apr 03 2012 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 3,350,000 | 3.2 M to 3.4 M (+3.88 %) |
Feb 27 2012 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | A | 0.10 | 41,667 | 4,317 | 41,667 | |
Feb 27 2012 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 141,667 | 0 | 141,667 | 0 to 141.7 K |
Feb 24 2012 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | A | 0.14 | 2,000,000 | 286,000 | 2,000,000 | |
Feb 24 2012 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | A | 0.14 | 125,000 | 17,875 | 125,000 | |
Feb 24 2012 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 3,000,000 | 0 | 3,225,000 | 225 K to 3.2 M (+1,333.33 %) |
Feb 24 2012 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 225,000 | 0 | 225,000 | 0 to 225 K |
Feb 24 2012 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | A | 0.12 | 83,333 | 9,917 | 83,333 | |
Feb 24 2012 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 183,333 | 0 | 183,333 | 0 to 183.3 K |
Jan 25 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.19 | 6,658,300 | 1,277,728 | 25,957,575 | 32.6 M to 26 M (-20.41 %) |
Jan 25 2012 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.18 | 1,000,000 | 175,400 | 32,615,875 | 33.6 M to 32.6 M (-2.97 %) |
Sep 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.15 | 608,225 | 93,058 | 33,615,875 | 34.2 M to 33.6 M (-1.78 %) |
Sep 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.15 | 108,080 | 16,320 | 34,224,100 | 34.3 M to 34.2 M (-0.31 %) |
Sep 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.15 | 10,000 | 1,520 | 34,332,180 | 34.3 M to 34.3 M (-0.03 %) |
Aug 25 2011 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Option Exercise | A | 0.45 | 5,000,000 | 2,250,000 | 5,000,000 | |
Aug 25 2011 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Option Exercise | A | 0.30 | 5,000,000 | 1,500,000 | 5,000,000 | |
Aug 25 2011 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Option Exercise | A | 0.19 | 10,000,000 | 1,850,000 | 10,000,000 | |
Aug 25 2011 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Grant | A | 0.00 | 10,000,000 | 0 | 15,087,430 | 5.1 M to 15.1 M (+196.56 %) |
Aug 18 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | A | 0.16 | 15,000,000 | 2,356,500 | 15,000,000 | |
Aug 18 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 15,000,000 | 0 | 34,342,180 | 19.3 M to 34.3 M (+77.55 %) |
Jun 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | M | 0.05 | 750,000 | 37,500 | 0 | |
Jun 30 2011 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Buy | M | 0.05 | 750,000 | 37,500 | 19,342,180 | 18.6 M to 19.3 M (+4.03 %) |
Jun 03 2011 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.20 | 750,000 | 150,525 | 5,087,430 | 5.8 M to 5.1 M (-12.85 %) |
May 25 2011 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.16 | 4,000 | 628 | 5,837,430 | 5.8 M to 5.8 M (-0.07 %) |
May 25 2011 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.16 | 781,755 | 128,208 | 5,841,430 | 6.6 M to 5.8 M (-11.80 %) |
May 25 2011 | ACTC | Ocata Therapeutics ... | Rabin Gary H | CEO & CFO | Sell | S | 0.16 | 414,245 | 64,208 | 6,623,185 | 7 M to 6.6 M (-5.89 %) |
Mar 08 2011 | ACTC | Ocata Therapeutics ... | Ruoslahti Erkki | Director | Sell | S | 0.17 | 100,000 | 16,600 | 2,744,119 | 2.8 M to 2.7 M (-3.52 %) |
Mar 08 2011 | ACTC | Ocata Therapeutics ... | Ruoslahti Erkki | Director | Sell | S | 0.17 | 150,000 | 25,050 | 2,844,119 | 3 M to 2.8 M (-5.01 %) |
Mar 08 2011 | ACTC | Ocata Therapeutics ... | Ruoslahti Erkki | Director | Sell | S | 0.17 | 250,000 | 41,650 | 2,994,119 | 3.2 M to 3 M (-7.71 %) |
Mar 07 2011 | ACTC | Ocata Therapeutics ... | Ruoslahti Erkki | Director | Sell | S | 0.17 | 250,000 | 42,500 | 3,244,119 | 3.5 M to 3.2 M (-7.15 %) |
Mar 03 2011 | ACTC | Ocata Therapeutics ... | Ruoslahti Erkki | Director | Sell | S | 0.18 | 10,630 | 1,866 | 3,494,119 | 3.5 M to 3.5 M (-0.30 %) |
Mar 01 2011 | ACTC | Ocata Therapeutics ... | Ruoslahti Erkki | Director | Sell | S | 0.18 | 250,000 | 43,750 | 3,504,749 | 3.8 M to 3.5 M (-6.66 %) |
Mar 01 2011 | ACTC | Ocata Therapeutics ... | Ruoslahti Erkki | Director | Sell | S | 0.18 | 72,050 | 12,609 | 3,754,749 | 3.8 M to 3.8 M (-1.88 %) |